The TNF-alpha inhibitors markets do not represent a unified market which can function differently by indication, for example, rheumatoid arthritis where more treatments options are available and inflammatory bowel disease where severe consequences can occur with treatment failure. The gene discussed is TNF; the disease is rheumatoid arthritis.